Extended-release naltrexone for youth with opioid use disorder

J Subst Abuse Treat
15 April 2021
https://pubmed.ncbi.nlm.nih.gov/34118699/

Background: Few published research studies have examined the effectiveness of extended-release naltrexone (XR-NTX) for the treatment of opioid use disorder (OUD) among adolescents and young adults.

Low-Dose Naltrexone May Be Opioid Replacement for Chronic Pain

Verywell Health
04 March 2021
https://www.verywellhealth.com/low-dose-naltrexone-may-be-opioid-replacement-for-chronic-pain-5115153

Effects of systemic opioid receptor ligands on ethanol- and sucrose seeking and drinking in alcohol-preferring (P) and Long Evans rats

Psychopharmacology (Berl)
November 2014
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209193/

Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study

J Addict Med
June 2018
https://pubmed.ncbi.nlm.nih.gov/29438157/

Naltrexone and nalmefene attenuate cocaine place preference in male mice

Neuropharmacology
15 September 2018
https://www.ncbi.nlm.nih.gov/pubmed/30048644

Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice

Pharmacol Biochem Behav
June 2019
https://pubmed.ncbi.nlm.nih.gov/30991059/

Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice

Brain Res
01 December 2019
https://pubmed.ncbi.nlm.nih.gov/31469985/

Early outcomes following low dose naltrexone enhancement of opioid detoxification

Am J Addict
April 2009
https://pubmed.ncbi.nlm.nih.gov/19283561/

Problem drinking and low-dose naltrexone-assisted opioid detoxification

J Stud Alcohol Drugs
May 2011
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084365/

A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence

Drug Alcohol Depend
15 July 2004
https://pubmed.ncbi.nlm.nih.gov/15225891/

Aim: To investigate the efficacy of low doses of naltrexone in relapse prevention for heroin dependence.

Design: Double blind, randomised comparison of three groups-Group 1 taking 50mg per day, Group 2: 0.5mg per day, and Group 3: 0.05 mg per day.